Literature DB >> 8040288

Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis.

M Ferretti1, V Casini-Raggi, T T Pizarro, S P Eisenberg, C C Nast, F Cominelli.   

Abstract

Administration of exogenous interleukin-1 receptor antagonist (IL-1ra) is effective in reducing the severity of disease in animal models of acute inflammation. However, the function of endogenous IL-1ra in this process, is not yet known. We investigated the pathophysiological role of IL-1ra in a rabbit model of formalin-immune complex colitis. This model has previously been shown to be IL-1 mediated and a reduction in disease severity is observed with exogenous IL-1ra treatment. Colonic IL-1ra was found to be elevated subsequent to IL-1, and exceeded IL-1 levels 10-fold. Peak levels of IL-1ra preceded both the resolution of colitis and a significant decrease in IL-1 production. Administration of specific neutralizing antibodies against rabbit IL-1ra increased mortality and prolonged intestinal inflammatory responses. A significant increase in IL-1 alpha colonic tissue levels was also measured as a result of exogenous anti-IL-1ra treatment. These studies are the first demonstration that endogenous IL-1ra may play an important role in regulating the host's inflammatory response by counteracting the deleterious and possibly lethal effects of IL-1 produced during acute inflammation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8040288      PMCID: PMC296330          DOI: 10.1172/JCI117345

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  25 in total

1.  cDNA cloning of an intracellular form of the human interleukin 1 receptor antagonist associated with epithelium.

Authors:  S Haskill; G Martin; L Van Le; J Morris; A Peace; C F Bigler; G J Jaffe; C Hammerberg; S A Sporn; S Fong
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

2.  Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor.

Authors:  C H Hannum; C J Wilcox; W P Arend; F G Joslin; D J Dripps; P L Heimdal; L G Armes; A Sommer; S P Eisenberg; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

3.  In vivo production of leukotriene B4 and leukotriene C4 in rabbit colitis. Relationship to inflammation.

Authors:  R D Zipser; C C Nast; M Lee; H W Kao; R Duke
Journal:  Gastroenterology       Date:  1987-01       Impact factor: 22.682

4.  Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor.

Authors:  W P Arend; F G Joslin; R J Massoni
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

5.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist.

Authors:  S P Eisenberg; R J Evans; W P Arend; E Verderber; M T Brewer; C H Hannum; R C Thompson
Journal:  Nature       Date:  1990-01-25       Impact factor: 49.962

6.  Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.

Authors:  F Cominelli; C C Nast; B D Clark; R Schindler; R Lierena; V E Eysselein; R C Thompson; C A Dinarello
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

Review 7.  Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis.

Authors:  W P Arend; J M Dayer
Journal:  Arthritis Rheum       Date:  1990-03

8.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

9.  Interleukin-1 (IL-1) receptor antagonist binds to the 80-kDa IL-1 receptor but does not initiate IL-1 signal transduction.

Authors:  D J Dripps; B J Brandhuber; R C Thompson; S P Eisenberg
Journal:  J Biol Chem       Date:  1991-06-05       Impact factor: 5.157

10.  Immune-complex mediated colitis in rabbits. An experimental model.

Authors:  H J Hodgson; B J Potter; J Skinner; D P Jewell
Journal:  Gut       Date:  1978-03       Impact factor: 23.059

View more
  47 in total

1.  Inflammatory bowel disease: definition, epidemiology, etiologic aspects, and immunogenetic studies.

Authors:  Bing Xia; JBA Crusius; SGM Meuwissen; AS Pe?a
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

2.  Toll-like receptor-7 ligand Imiquimod induces type I interferon and antimicrobial peptides to ameliorate dextran sodium sulfate-induced acute colitis.

Authors:  Satheesh K Sainathan; Kumar S Bishnupuri; Konrad Aden; Qizhi Luo; Courtney W Houchen; Shrikant Anant; Brian K Dieckgraefe
Journal:  Inflamm Bowel Dis       Date:  2011-09-26       Impact factor: 5.325

Review 3.  Intestinal mucosal responses to microbial infection.

Authors:  Lars Eckmann; Martin F Kagnoff
Journal:  Springer Semin Immunopathol       Date:  2005-06-01

4.  Novel cytokine signaling pathways in inflammatory bowel disease: insight into the dichotomous functions of IL-33 during chronic intestinal inflammation.

Authors:  Luca Pastorelli; Carlo De Salvo; Marissa A Cominelli; Maurizio Vecchi; Theresa T Pizarro
Journal:  Therap Adv Gastroenterol       Date:  2011-09       Impact factor: 4.409

5.  Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis.

Authors:  U T Hacker; M Gomolka; E Keller; A Eigler; C Folwaczny; H Fricke; E Albert; K Loeschke; S Endres
Journal:  Gut       Date:  1997-05       Impact factor: 23.059

6.  Mechanism of interleukin-1β induced-increase in mouse intestinal permeability in vivo.

Authors:  Rana Al-Sadi; Shuhong Guo; Karol Dokladny; Matthew A Smith; Dongmei Ye; Archana Kaza; D Martin Watterson; Thomas Y Ma
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

7.  The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.

Authors:  D Burger; R Chicheportiche; J G Giri; J M Dayer
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

Review 8.  Curcumin: an orally bioavailable blocker of TNF and other pro-inflammatory biomarkers.

Authors:  Bharat B Aggarwal; Subash C Gupta; Bokyung Sung
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

9.  Upregulation of RGS4 and downregulation of CPI-17 mediate inhibition of colonic muscle contraction by interleukin-1beta.

Authors:  Wenhui Hu; Sunila Mahavadi; Fang Li; Karnam S Murthy
Journal:  Am J Physiol Cell Physiol       Date:  2007-10-24       Impact factor: 4.249

Review 10.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.